Treatment of Advanced Ovarian Cancer, with Thomas Herzog, MD: Case 1

Video

Treatment of Advanced Ovarian Cancer, with Thomas Herzog, MD

May 2015

  • A 56-year-old woman presented to her gynecologist with urinary frequency and persistent abdominal bloating. The patient reports maintaining normal activities and a moderate exercise.
    • PMH: Hypertension, well-controlled or spironolactone
    • Abdominal ultrasound showed a complex mass in the right pelvis measuring 4.5 X 5.0 X 7.5 cm
    • Physical exam: fluid wave test positive for ascites
    • CA-125, 622 U/ml
  • She was referred to a gynecologic oncologist for further evaluation.
  • CT of the pelvis and abdomen showed a right complex pelvic mass, ascites, and omental cake. No other peritoneal lesions were visualized.
  • Based on CT findings, she was scheduled for surgery.
  • The patient underwent complete resection with no residual disease remaining.
  • Diagnosis, epithelial ovarian cancer, stage IIIC
  • She received 6 cycles of carboplatin every 3 weeks (AUC 6) and weekly paclitaxel (80 mg/m2) for 18 weeks.
  • Follow up labs showed normalization of CA-125 to less than 10 U/ml

April 2017

  • Almost 2 years later, the patient reported having symptoms of persistent abdominal distention and weight loss. She reports feeling tired and napping during the day.
    • CA-125 level, 330 U/ml
    • CT scan showed peritoneal seeding consistent with carcinomatosis
  • Diagnosis: platinum-sensitive recurrent ovarian cancer
  • The patient was started on bevacizumab (15 mg/kg) plus 6 cycles of carboplatin (AUC 5) and paclitaxel (175 mg/m2) every 3 weeks with a plan for bevacizumab maintenance therapy.
  • After 2 cycles of therapy, she developed grade 2 hypertension (156/94 mm Hg); this was subsequently controlled by adding an ACE inhibitor to her diuretic.
  • The patient has continued therapy without incident.
Related Videos
Video 3 - "Managing Toxicities and Adverse Reactions in HR+/Her2-Low mBC Therapies"
Video 2 - "EMERALD: Underscoring Key Elacestrant Data + Subgroup Analyses for Informed Therapy Selection"
Video 1 - "A 62-Year-Old Woman with HR+ HER2-low Metastatic Breast Cancer and Lung, Liver, and Bone Metastases and Using Biomarker Testing to Guide Treatment Selection"
John Mascarenhas, MD, an expert on myelofibrosis
John Mascarenhas, MD, an expert on myelofibrosis
Related Content